Benitec Biopharma INC 8-K filings

Benitec Biopharma appoints David Friedman to the Board of Directors while CFO Megan Boston rotates off the Board.

Benitec Biopharma announced Q3 2026 financial results and provided an operational update highlighting positive interim clinical data for its BB-301 gene therapy candidate for OPMD.

Benitec Biopharma announced its Q2 2026 financial results and positive clinical data for its OPMD gene therapy candidate, BB-301, showing durable efficacy.

Benitec Biopharma Inc. announced that its stockholders approved all proposals, including director elections and executive compensation, at the 2025 Annual Meeting.

Benitec Biopharma announced positive interim Phase 1b/2a trial results for BB-301, achieving a 100% responder rate, securing FDA Fast Track Designation, and completing a $100 million public offering.

Benitec Biopharma Inc. announced the pricing of a combined underwritten public offering and registered direct offering, expecting to raise approximately $100 million in gross proceeds.

Benitec Biopharma announced positive interim clinical results for its BB-301 OPMD treatment, achieving a 100% responder rate in Cohort 1, and received FDA Fast Track Designation.

Benitec Biopharma announced its full year 2025 financial results and provided an operational update on its BB-301 clinical development program for OPMD.

Benitec Biopharma Inc. announced that its Audit Committee concluded that previously issued financial statements for Q2 and Q3 2025 should no longer be relied upon due to incorrect share-based compensation expense recording.

Benitec Biopharma Inc. announced a positive recommendation from its Data Safety Monitoring Board to continue enrollment in its Phase 1b/2a clinical study for BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy, with Cohort 2 enrollment expected to begin in Q4 2025.

Benitec Biopharma reported its third quarter 2025 financial results, highlighting increased expenses related to the ongoing clinical development of BB-301 for OPMD and provided an update on patient enrollment.

Benitec Biopharma successfully closes its previously announced public offering, raising approximately $27.8 million through the sale of common stock and pre-funded warrants.

Benitec Biopharma Inc. has entered into a Registration Rights Agreement with Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. to register for resale shares of the company's common stock sold in a recent direct offering.

Benitec Biopharma Inc. announces the pricing of a $30 million offering of common stock and pre-funded warrants, including a concurrent registered direct offering with Suvretta Capital.

Benitec Biopharma reports continued improvements in swallowing function and reduced dysphagic symptoms in OPMD patients treated with BB-301 in an ongoing Phase 1b/2a study.

Benitec Biopharma reports positive interim clinical data from its BB-301 Phase 1b/2a study, showing durable improvements in swallowing function for OPMD patients.

Benitec Biopharma reported its second quarter 2025 financial results, highlighting ongoing clinical trials for BB-301 and upcoming presentations at the Muscular Dystrophy Association Conference.

Benitec Biopharma has appointed Sophie Mukadam as Chief Operating Officer, effective January 1, 2025, and granted her stock options.

Benitec Biopharma has appointed a new Chief Operating Officer, confirmed its CFO, and granted significant stock options to key executives.

Benitec Biopharma Inc. has officially amended its certificate of incorporation to authorize the issuance of 5 million preferred shares, effective December 9, 2024.

Benitec Biopharma Inc. successfully held its 2024 Annual Meeting, with stockholders approving the election of directors, ratification of the accounting firm, executive compensation, and an amendment to authorize additional preferred stock.

Benitec Biopharma announced positive interim clinical study results for its BB-301 gene therapy and its financial results for the first fiscal quarter of 2025, ending September 30, 2024.

Benitec Biopharma's Compensation Committee approved discretionary bonus payments for its Executive Chairman and CEO, Dr. Jerel Banks, and Executive Director, Megan Boston, for their performance during the fiscal year ending June 30, 2024.

Benitec Biopharma reported positive interim results from its Phase 1b/2a study of BB-301 gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD), showing clinically meaningful improvements in swallowing for the first two treated subjects.

Benitec Biopharma has entered into a sales agreement to potentially sell up to $75 million of its common stock through an at-the-market offering.

Benitec Biopharma raised approximately $21.1 million through warrant exercises, with Suvretta Capital increasing its stake to 49.9% after waiving a previous ownership limitation.

Benitec Biopharma announced positive interim clinical trial results for its OPMD treatment, BB-301, and the closing of a $40 million private placement, extending its cash runway through 2025.

Benitec Biopharma stockholders approved an amendment to the company's 2020 Equity and Incentive Compensation Plan at a special meeting held on August 29, 2024.

Benitec Biopharma announced positive 180-day interim results from its Phase 1b/2a study of BB-301 gene therapy for OPMD, showing continued improvements in swallowing efficiency.

Benitec Biopharma has appointed Kishen Mehta to its board of directors, effective June 26, 2024, following a $40 million private investment led by Suvretta Capital.